49 results on '"DeVita MV"'
Search Results
2. Long-term follow-up after subtotal parathyroidectomy in patients with renal failure.
- Author
-
Yu I, DeVita MV, Komisar A, Yu, I, DeVita, M V, and Komisar, A
- Abstract
Objectives/hypothesis: The most appropriate type of surgery for hyperparathyroidism secondary to renal failure remains controversial. We report a 5-year experience of patients with hyperparathyroidism secondary to end-stage renal disease who underwent subtotal parathyroidectomy. We believe that this is the procedure of choice, offering several advantages over total parathyroidectomy with and without reimplantation.Study Design: Retrospective review.Methods: Review of 14 consecutive renal failure patients who underwent subtotal parathyroidectomy by one surgeon (A.K.) was performed. Follow-up ranged from 4 to 54 months. All patients were receiving chronic maintenance dialysis. All patients came to surgery with clinical symptoms of parathyroid bone disease, elevated serum calcium levels (10.1-12.4 mg/dL), and intact parathyroid hormone levels (619-4160 pg/mL), despite maximal medical therapy. At exploration four glands were identified in all patients and three and a half were removed.Results: All patients experienced symptomatic relief postoperatively with normalization or near-normalization of serum calcium concentration and intact parathyroid hormone concentrations. One patient developed recurrent disease 4 months after surgery, and on re-exploration a supernumerary substernal gland was identified. A second patient developed recurrent symptoms 4 years after surgery and at the time of this writing was awaiting re-exploration.Conclusions: All patients had either resolution of or marked improvement in their subjective complaints. There have been no cases of permanent hypoparathyroidism. We believe that subtotal parathyroidectomy is the best procedure for patients with refractory symptoms of secondary hyperparathyroidism. [ABSTRACT FROM AUTHOR]- Published
- 1998
3. Shorter observation times and smaller gauge needles in outpatient kidney biopsies.
- Author
-
Giniyani LL, McGee J, DeVita MV, Rahman RT, Moses AA, and Rosenstock JL
- Subjects
- Humans, Female, Male, Time Factors, Middle Aged, Retrospective Studies, Biopsy, Needle instrumentation, Biopsy, Needle methods, Biopsy, Needle adverse effects, Adult, Aged, Equipment Design, Ambulatory Care, Kidney Diseases pathology, Kidney pathology, Needles
- Abstract
Controversy exists as to the optimal observational time (OT) after outpatient percutaneous kidney biopsy. Further, there is some uncertainty about the benefit of smaller (18-gauge) vs. larger (16-gauge) biopsy needles. At our institution, we have been lowering the OT after outpatient kidney biopsies. Initially in 2015, we were monitoring for 6 hours and gradually began to decrease the OT over time. From 2020, we have adopted an OT of less than 4 hours. During this time period (in 2018), we also began using a smaller gauge needle (18 gauge). We reviewed all outpatient kidney biopsies performed by the nephrology division at our institution since 2015. There were 137 biopsies reviewed. 63 had OT of 4 - 6 hours, and 74 had OT < 4 hours. There was a total of 4 significant complications (2.9%). Two complications, symptomatic retroperitoneal bleeds, were detected in less than 3 hours. The other 2 complications were seen at 9 hours (clot retention) and 72 hours (retroperitoneal bleed after anticoagulation restarted). 63% of the biopsies were done using 18-gauge needles with 1 complication in this group vs. 3 in the 16-gauge group. All cases had adequate tissue for interpretation based on the ability to make a kidney diagnosis. The number of glomeruli obtained in the 18-gauge group was 29 ± 13 glomeruli, and in the 16-gauge group was 25 ± 10, which did not differ between groups. In summary, in an outpatient population, all significant post-biopsy complications were evident either within the first 3 hours or after 9 hours, and this suggests the feasibility of using shorter than standard OT in outpatient kidney biopsies. Furthermore, an 18-gauge needle may lower the risk of complications and obtain adequate tissue.
- Published
- 2024
- Full Text
- View/download PDF
4. Implication of acute tubular injury in minimal change nephrotic syndrome.
- Author
-
Grainer H, DeVita MV, Leung TM, Bijol V, and Rosenstock JL
- Subjects
- Adult, Humans, Male, Kidney, Retrospective Studies, Nephrosis, Lipoid complications, Nephrotic Syndrome complications, Acute Kidney Injury diagnosis, Acute Kidney Injury epidemiology, Acute Kidney Injury etiology
- Abstract
While acute tubular injury (ATI) is known to occur in a significant number of minimal change disease (MCD) nephrotic syndrome cases with acute kidney injury (AKI), the clinical significance is not certain, and AKI may also occur without ATI. This study aimed to evaluate whether the severity of AKI defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria correlated with the presence or severity of ATI in a series of adult patients with MCD. We also looked at whether time to remission of nephrotic syndrome (NS) with treatment correlated with the presence of ATI in those with and without AKI. We excluded patients with secondary MCD. Of 61 patients, 20 had AKI (33%). ATI was significantly more likely to occur in those with AKI than in those without AKI (60 vs. 24%). Overall, the severity of AKI did not clearly correspond with the severity of ATI. Remission rates at 4 weeks were lowest (25%) in those with both AKI and ATI, while they were highest (100%) in those with neither AKI nor ATI. Patients with AKI but no ATI and those with no AKI but having ATI were intermediate in remission rates and similar to each other (60 and 62%, respectively). The time to remission in the group of those without AKI was significantly longer in those with ATI than in those without (p = 0.0027), but the numerical difference in remission did not reach statistical significance in the smaller group of AKI patients. Patients with ATI were older and more often male than those without ATI. It appears that having ATI may predict a slower remission rate in MCD though the reason for this is unclear. The different demographics of those with ATI may also play a role.
- Published
- 2024
- Full Text
- View/download PDF
5. Oxalate nephropathy: a review.
- Author
-
Rosenstock JL, Joab TMJ, DeVita MV, Yang Y, Sharma PD, and Bijol V
- Abstract
This review describes the clinical and pathological features of oxalate nephropathy (ON), defined as a syndrome of decreased renal function associated with deposition of calcium oxalate crystals in kidney tubules. We review the different causes of hyperoxaluria, including primary hyperoxaluria, enteric hyperoxaluria and ingestion-related hyperoxaluria. Recent case series of biopsy-proven ON are reviewed in detail, as well as the implications of these series. The possibility of antibiotic use predisposing to ON is discussed. Therapies for hyperoxaluria and ON are reviewed with an emphasis on newer treatments available and in development. Promising research avenues to explore in this area are discussed., (© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2021
- Full Text
- View/download PDF
6. Two Cases of Proliferative Glomerulonephritis With Monoclonal IgG Deposits Treated With Renin Angiotensin Inhibition Alone With Long-term Follow-up.
- Author
-
Rosenstock JL, Vynnyk M, DeVita MV, and D'Agati VD
- Published
- 2021
- Full Text
- View/download PDF
7. Adult primary nephrotic syndrome trends by race: a diminished frequency of focal segmental glomerulosclerosis in non-black patients.
- Author
-
Mbakop C, DeVita MV, Wahl SJ, Bijol V, and Rosenstock JL
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, United States epidemiology, Glomerulosclerosis, Focal Segmental epidemiology, Nephrotic Syndrome epidemiology, Racial Groups statistics & numerical data
- Abstract
Purpose: There have been conflicting data on the relative frequency of common forms of primary nephrotic syndrome (PNS). We undertook this study to look at the causes of PNS in the latest decade from our biopsy population, with a special attention to breakdown by race., Methods: Retrospective chart review of all cases of adult PNS extracted from a database of 1388 cases for the last 10 years. We were careful to exclude patients with secondary disease and without the full nephrotic syndrome., Results: There were 115 cases of PNS. Overall, MN was the most common lesion (40.0%), followed by minimal change disease (MCD) (34.0%), focal segmental glomerulosclerosis (FSGS) (13.0%), and IgA nephropathy (IgAN) (11.3%). Among whites, MN was the most common cause of NS (41.7%), followed by MCD (33.3%), IgAN (16.7%), and FSGS (6.3%). Among blacks, FSGS was the most common lesion (33.3%) followed closely by MN (29.6%), and MCD (26.0%). IgAN was present in 7.4%. Among multiracial patients (MR), MGN was the most common (50%) followed by MCD (45.5%) and FSGS (4.5%). In Asians, MCD (50.1%) and MGN (33.3%) were the most common, followed by FSGS and IgAN with 8.3% each., Conclusions: MN and MCD were the most common causes of PNS in our population, with FSGS much less common overall. This is especially the case among whites and MR. Among blacks, MN and FSGS were almost codominant causes. The apparent decreased prevalence of FSGS may be related to more effective exclusion of secondary and maladaptive causes.
- Published
- 2021
- Full Text
- View/download PDF
8. Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19.
- Author
-
Golmai P, Larsen CP, DeVita MV, Wahl SJ, Weins A, Rennke HG, Bijol V, and Rosenstock JL
- Subjects
- Autopsy, Biopsy, COVID-19, Humans, Kidney ultrastructure, Microscopy, Electron, Pandemics, SARS-CoV-2, Acute Kidney Injury pathology, Betacoronavirus, Coronavirus Infections pathology, Kidney pathology, Pneumonia, Viral pathology
- Published
- 2020
- Full Text
- View/download PDF
9. Novel Approaches to Arteriovenous Access Creation, Maturation, Suitability, and Durability for Dialysis.
- Author
-
DeVita MV, Khine SK, and Shivarov H
- Abstract
Since the arteriovenous fistula (AVF) was first conceived over 50 years ago, the goal to create a vascular conduit with predictable and reproducible maturation and durability continues to elude caregivers. Recently, however, advances in the understanding of vascular biology and new technologies now provides us with some optimism; we are moving toward a viable solution. A quickly maturing, sustainable, and durable arteriovenous access may soon be attainable. This review will discuss these advances. There are novel approaches to AVF creation and devices to enhance maturation, advances in arteriovenous graft material(s), and devices to safely prolong the use of tunneled dialysis catheters. Although hemodialysis (HD) access remains a complex problem, these innovations may lead the way to optimizing the care and the quality of life of those patients who have no choice but to proceed with HD., (© 2020 International Society of Nephrology. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
10. Use of lung ultrasonography to determine the accuracy of clinically estimated dry weight in chronic hemodialysis patients.
- Author
-
Jiang C, Patel S, Moses A, DeVita MV, and Michelis MF
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Pulmonary Edema diagnostic imaging, Body Fluids diagnostic imaging, Kidney Failure, Chronic therapy, Lung diagnostic imaging, Renal Dialysis, Ultrasonography
- Abstract
Purpose: The use of lung ultrasound (LUS) to identify extravascular lung water has received increasing acceptance. Sonographic B-lines, discrete vertical lines that originate from the pleura, represent pulmonary edema and are correlated with the accumulation of fluid. The goal of this study was to evaluate the utility of LUS to determine the accuracy of prescribed dry weight (DW) in chronic hemodialysis (HD) patients and to ascertain the adequacy of fluid removal., Methods: LUS was scheduled to be performed pre- and post-HD in 20 patients. The HD prescription and DW challenge were done independent of the results of the LUS. The presence of B-lines was tabulated and compared to the intradialytic ultrafiltration parameters., Results: Of the 20 patients, 3 did not exhibit B-lines at the first dialysis session. In regard to the other 17 patients, B-lines disappeared in 7 patients at the end of the HD session (mean B-lines 4.2-0). One patient was 0.3 kg away from the prescribed dry weight, but the 6 patients were a mean of 1.7 kg below DW. Of the remaining 10 patients, eight decreased but did not eliminate the B-lines (mean B-lines 15.5-3.8) and were a mean of 3.8 kg below DW post-HD. Two patients who exhibited more cardiac insufficiency than initially recognized could not reach DW or eliminate the B-lines. Eight patients who had residual B-lines at the end of the first HD session had their DW re-estimated and had a second session. Two were able to eliminate the B-lines (mean 2.5-0) and reached a mean of 1.2 kg below DW. Six did not eliminate the B-lines (mean 11.5-4.2) but were able to reach a mean of 0.6 kg below DW. Correlation analysis showed a statistically significant correlation (P < 0.05) between the intradialytic percent change in B-lines and the percent change in total body weight (r = 0.40) and ultrafiltration rate (r = 0.33). Seven of 10 patients with clear chest X-rays pre-HD exhibited B-lines., Conclusions: This study supports the hypothesis that reduction in B-lines during HD can provide accurate information regarding changes in pulmonary fluid content. Further, LUS is a valuable diagnostic tool for recognizing both the adequacy of fluid removal and the occurrence of error in the estimation of dry weight by usual clinical parameters.
- Published
- 2017
- Full Text
- View/download PDF
11. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency.
- Author
-
Sultana T, DeVita MV, and Michelis MF
- Subjects
- Administration, Oral, Adult, Aged, Dietary Supplements, Erythropoiesis drug effects, Female, Ferritins blood, Hemoglobins metabolism, Humans, Male, Middle Aged, Prospective Studies, Renal Dialysis adverse effects, Transferrin metabolism, Ascorbic Acid administration & dosage, Erythropoietin administration & dosage, Iron blood, Iron Deficiencies, Renal Insufficiency, Chronic therapy, Vitamins administration & dosage
- Abstract
Purpose: Functional iron deficiency (FID) is a major cause of persistent anemia in dialysis patients and also contributes to a suboptimal response to erythropoietin (Epo) administration. Vitamin C acts as an enzyme cofactor and enhances mobilization of the ferrous form of iron to transferrin thus increasing its bioavailability. High-dose intravenous vitamin C has been shown to decrease the Epo requirement and improve hemoglobin levels in previous studies. This study assessed the effect of low-dose oral vitamin C on possible reduction in Epo dose requirements in stable hemodialysis patients with FID., Methods: This prospective study included 22 stable hemodialysis patients with FID defined as transferrin saturation (T sat) <30 % and ferritin levels of >100 mcg/L with Epo requirement of ≥4000 U/HD session. Patients received oral vitamin C 250 mg daily for 3 months. Hemoglobin, iron and T sat levels were recorded monthly. No one received iron supplementation during the study period., Results: There was a significant reduction in median Epo dose requirement in the 15 patients who completed the study, from 203.1 U/kg/week (95 % CI 188.4-270.6) to 172.8 U/kg/week (95 % CI 160.2-214.8), (P = 0.01). In the seven responders, there was 33 % reduction in Epo dose from their baseline. Despite adjustment of Epo dose, the mean hemoglobin level was significantly increased from 10.1 ± 0.6 to 10.7 ± 0.6 mg/dL (P = 0.03). No adverse effects of oral vitamin C were observed., Conclusion: Daily low-dose oral vitamin C supplementation reduced Epo dose requirements in hemodialysis patients with FID. Limitations of this study include a small sample size and the lack of measurements of vitamin C and oxalate levels. Despite concerns regarding oral vitamin C absorption in dialysis patients, this study indicates vitamin C was well tolerated by all participants without reported adverse effect.
- Published
- 2016
- Full Text
- View/download PDF
12. Advanced CKD: Preparing for a Storm to Avoid a Disaster.
- Author
-
DeVita MV
- Subjects
- Disease Progression, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic physiopathology, Patient Education as Topic, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic therapy, Kidney Failure, Chronic therapy, Renal Replacement Therapy
- Published
- 2016
- Full Text
- View/download PDF
13. Epidemiology and Challenges to the Management of Advanced CKD.
- Author
-
Hazzan AD, Halinski C, Agoritsas S, Fishbane S, and DeVita MV
- Subjects
- Communication, Disease Progression, Glomerular Filtration Rate, Humans, Patient Care Planning, Renal Insufficiency, Chronic physiopathology, Treatment Failure, Cardiovascular Diseases epidemiology, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic therapy
- Abstract
Advanced CKD is a period of CKD that differs greatly from earlier stages of CKD in terms of treatment goals. Treatment during this period presents particular challenges as further loss of kidney function heralds the need for renal replacement therapy. Successful management during this period increases the likelihood of improved transitions to ESRD. However, there are substantial barriers to optimal advanced CKD care. In this review, we will discuss advanced CKD definitions and epidemiology and outcomes., (Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
14. A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin.
- Author
-
Mavani GP, DeVita MV, and Michelis MF
- Abstract
The pressor and antidiuretic actions of arginine vasopressin (AVP) have been well documented. This review focuses on the less widely appreciated actions of AVP which also have important physiologic functions and when better understood may provide important insights into common disease states. These actions include effects on pain perception and bone structure as well as important relationships to the varied components of metabolic syndrome. These include effects on blood glucose, lipid levels, and blood pressure. AVP may also play a role in the progression of chronic kidney disease and effect physiologic changes relating to aging, abnormal social behavior, and cognitive function. Important cellular responses including cell proliferation, inflammation, and control of infection and their relationship to AVP are described. Finally, the effects of AVP on hemostasis and the hypothalamic-pituitary-adrenal axis are noted. The goal of this summary of the various actions of AVP is to direct attention to the potential benefits of research in these underemphasized areas of importance.
- Published
- 2015
- Full Text
- View/download PDF
15. Mycophenolate mofetil as a steroid-sparing agent in sarcoid-associated renal disease.
- Author
-
Zaidi AA, DeVita MV, Michelis MF, and Rosenstock JL
- Subjects
- Acute Kidney Injury drug therapy, Female, Humans, Kidney Diseases physiopathology, Middle Aged, Mycophenolic Acid therapeutic use, Sarcoidosis physiopathology, Kidney Diseases drug therapy, Mycophenolic Acid analogs & derivatives, Sarcoidosis drug therapy
- Abstract
Steroids are the mainstay of treatment for renal sarcoidosis. Many patients with sarcoidosis are chronically dependent on steroids and there is limited data on the use of steroid-sparing agents. This is a case of a patient that has remained in remission using mycophenolate mofetil (MMF) as a steroid-sparing agent. The patient is a 56-year-old female with a history of sarcoidosis diagnosed by lymph node biopsy who developed 3 episodes of acute kidney injury (AKI) in the setting of exacerbations of her sarcoidosis, each responding to prednisone treatment. Due to possible lifelong need for prednisone, MMF was started as a steroid-sparing treatment. She tolerated the MMF well and has now been steroidfree for 22 months. There have been only a few case reports about the use of MMF as a steroid-sparing agent in sarcoid-associated renal disease, in which patients could be successfully weaned off steroids. This is the longest reported follow-up of a patient being off steroids while on MMF. It is also notable for the patient having a relapse on the MMF which responded to an increased dose. MMF should be studied further as a potential steroid-sparing agent in the treatment of sarcoid associated renal disease.
- Published
- 2015
- Full Text
- View/download PDF
16. Novel use for aquapheresis in a patient with severe volume overload post massive transfusion.
- Author
-
Sumin X and Devita MV
- Subjects
- Adenocarcinoma complications, Adenocarcinoma diagnosis, Aged, 80 and over, Edema etiology, Female, Follow-Up Studies, Gastrectomy methods, Gastrointestinal Hemorrhage etiology, Humans, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic therapy, Risk Assessment, Severity of Illness Index, Stomach Neoplasms diagnosis, Treatment Outcome, Adenocarcinoma surgery, Edema therapy, Gastrointestinal Hemorrhage therapy, Stomach Neoplasms surgery, Transfusion Reaction, Ultrafiltration methods
- Published
- 2014
17. Preventing the progression of chronic kidney disease: two case reports and review of the literature.
- Author
-
Toor MR, Singla A, Kim JK, Sumin X, DeVita MV, and Michelis MF
- Subjects
- Aged, Disease Progression, Female, Fibroblast Growth Factor-23, Follow-Up Studies, Humans, Male, Middle Aged, Renal Insufficiency, Chronic prevention & control, Renal Replacement Therapy methods
- Abstract
A variety of therapeutic modalities are available to alter the abnormalities seen in patients with chronic kidney disease (CKD). A comprehensive plan can now be developed to slow the progression of CKD. Two clinical cases of delay in the need for renal replacement therapy are described. This delay was achieved by using recognized recommendations for optimal diabetes therapy (HbA1c target 7 %), goals for blood pressure levels, reduction of proteinuria, and the proper use of ACEI/ARB therapies. Recent recommendations include BP <140/90 mmHg for patients <60 years old and <150/90 mmHg for older patients unless they have CKD or diabetes. Limits on dietary sodium and protein intake and body weight reduction will decrease proteinuria. Proper treatment for elevated serum phosphorous and parathyroid hormone levels is now appreciated as well as the benefits of therapy for dyslipidemias and anemia. Concerns regarding unfavorable outcomes with excess ESA therapy have led to hemoglobin goals in the 10-12 g/dL range. Finally, new therapeutic considerations for the treatment of acidosis and hyperuricemia are presented with data available to suggest that increasing serum bicarbonate to >22 mmol/L is beneficial, while serum uric acid therapeutic goals are still uncertain. Also, two as yet insufficiently understood approaches to altering the course of CKD (FGF-23 level reduction and balancing gut microbiota) are noted.
- Published
- 2014
- Full Text
- View/download PDF
18. Neurofibromatosis type 1-associated hypertension secondary to coarctation of the thoracic aorta.
- Author
-
Mavani G, Kesar V, Devita MV, Rosenstock JL, Michelis MF, and Schwimmer JA
- Abstract
Neurofibromatosis type 1 (NF-1), also known as von Recklinghausen's disease, is an autosomal dominant genetic disorder. NF-I vasculopathy has been used to describe various vascular malformations associated with NF-1. Secondary hypertension related to NF-1 vasculopathy has been reported because of renal artery stenosis, coarctation of the abdominal aorta and other vascular lesions; however, coarctation of the thoracic aorta has seldom been reported. We report the first case, to our knowledge, of isolated coarctation of thoracic aorta in a pregnant female with NF-1. Healthcare providers caring for patients with NF-1 should be aware of associated vascular complications.
- Published
- 2014
- Full Text
- View/download PDF
19. Characteristics, therapies, and factors influencing outcomes of hospitalized hypernatremic geriatric patients.
- Author
-
Toor MR, Singla A, DeVita MV, Rosenstock JL, and Michelis MF
- Subjects
- Aged, Aged, 80 and over, Critical Care, Female, Hospital Mortality, Hospitalization, Humans, Hypernatremia etiology, Length of Stay, Male, Nephrology, Osmolar Concentration, Retrospective Studies, Sodium blood, Sodium urine, Treatment Outcome, Fluid Therapy methods, Hypernatremia mortality, Hypernatremia therapy, Referral and Consultation
- Abstract
Purpose: Hypernatremia is a common electrolyte disorder associated with adverse outcomes such as increased length of stay and mortality due to a variety of factors. Our aim was to investigate known factors as well as other variables which we had identified in hospitalized hypernatremic geriatric patients and their relationship to patient outcomes., Methods: A retrospective chart review of all adult hospitalized patients in a 4-month period with a serum sodium level >150 mmol/L was performed. Factors evaluated included use of a nephrology consultation, certain urine laboratory measures, fluids employed, rate of correction, and patient's level of care setting. Outcome measures included length of stay and mortality., Results: The patient mortality rate was 52 %. Mean age was 79.6 years (n = 33), and mean initial sodium level was 152.6 mmol/L. Plasma and urine osmolality, and urine sodium concentration were checked in less than 25 % of patients. Fifteen of 18 patients in the ICU expired, whereas only 2 of 15 patients not in the ICU expired (p < 0.0004, OR 32.50, CI 95 % (4.68-225.54)). Of the 23 patients (70 %) who had their serum sodium level corrected, 11 were corrected in ≤3 days and 12 in >3 days, but this difference did not affect mortality rate (45 vs. 50 %, p = 0.99). The mortality rate was similar (60 %, p = 0.52) for those whose serum sodium level never corrected suggesting that correction did not influence outcomes. The fluids chosen for therapy of the hypernatremia were appropriate to the patients volume status. Five of 15 patients who received a nephrology consultation survived, while 11 of 18 patients without a nephrology consultation survived (p = 0.12). The mean length of stay was 25.0 ± 23.9 days and no different for those who expired versus those who survived (25.2 ± 21.2 vs. 24.8 ± 25.9 days, p = 0.96)., Conclusions: Hypernatremia is associated with a poor prognosis, and outcomes are still disappointing despite appropriate rates of correction, intensive monitoring, and the involvement of a nephrologist. Strategies directed at avoidance of the development of hypernatremia and attention to concomitant disease may provide significant patient benefit.
- Published
- 2014
- Full Text
- View/download PDF
20. Cytomegalovirus-induced collapsing focal segmental glomerulosclerosis.
- Author
-
Grover V, Gaiki MR, DeVita MV, and Schwimmer JA
- Abstract
Collapsing glomerulopathy is an aggressive morphologic variant of focal segmental glomerulosclerosis which typically presents with nephrotic syndrome and rapidly progressive renal failure. Most cases of collapsing glomerulopathy are associated with human immunodeficiency virus infection. We present a rare case of collapsing glomerulopathy associated with acute cytomegalovirus (CMV) infection in an immunocompetent host with improvement in renal function after the treatment of CMV with ganciclovir. CMV may be an under-recognized cause of collapsing glomerulopathy which may respond to antiviral treatment.
- Published
- 2013
- Full Text
- View/download PDF
21. Massive intravascular hemolysis with mechanical rheolytic thrombectomy of a hemodialysis arteriovenous fistula.
- Author
-
Carrera LA, Reddy R, Pamoukian VN, Michelis MF, DeVita MV, and Rosenstock J
- Subjects
- Arteriovenous Shunt, Surgical, Humans, Male, Middle Aged, Thromboembolism etiology, Treatment Failure, Hemolysis, Kidney Failure, Chronic therapy, Mechanical Thrombolysis methods, Renal Dialysis adverse effects, Thromboembolism therapy
- Abstract
A 57-year-old man with chronic kidney disease stage 5 presented for ambulatory evaluation of his arteriovenous fistula. He underwent rheolytic thrombectomy with tissue plasminogen activator infusion, angioplasty, and brachial artery stenting under local sedation. His immediate postoperative course was complicated by hypotension, cardiac dysrhythmias and hyperkalemia requiring emergent hemodialysis, due to severe intravascular hemolysis. This case illustrates that mechanical thrombectomy can cause clinically significant intravascular hemolysis, thus careful postoperative monitoring is recommended., (© 2012 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
22. Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay.
- Author
-
Gaiki MR, DeVita MV, Michelis MF, Panagopoulos G, and Rosenstock JL
- Subjects
- Asymptomatic Diseases, Biomarkers blood, Blood Chemical Analysis statistics & numerical data, Female, Heart Diseases diagnosis, Humans, Kidney Failure, Chronic blood, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Male, Middle Aged, Pilot Projects, Prognosis, Heart Diseases blood, Heart Diseases etiology, Renal Dialysis, Troponin I blood
- Abstract
Elevated troponin T is known to be a prognostic marker for long-term cardiac events and mortality in asymptomatic end-stage renal disease patients. There are conflicting data in this regard with respect to troponin I (TnI). We recently showed a high incidence of elevated TnI levels in asymptomatic hemodialysis (HD) patients using a new generation sensitive TnI assay. The aim of this pilot study was to explore the prognostic value of TnI, as measured with this new assay, as a marker for outcomes in HD patients over a 2-year follow-up period. Fifty-one asymptomatic HD patients were enrolled, and pre-dialysis TnI levels were checked once monthly over 3 consecutive months. Patients were considered to be in the TnI positive group if TnI level on any of the three draws was ≥0.035 ng/ml. All patients were followed for a period of 2 years. The primary end points were acute coronary syndrome, coronary revascularization, sudden death, or cardiac arrest. The secondary end point was all-cause mortality. Elevated TnI levels were found in 51% (26/51) of patients in our cohort. One TnI positive patient was subsequently lost to follow up. There were 6 cardiac events over 2 years, all of which were in the troponin positive group (6/25 or 24%). The presence of a positive TnI at baseline was significantly associated with future cardiac events (p=0.022). A prior history of coronary artery disease (CAD) was also significantly related to future cardiac events (p=0.010). No patient with negative TnI at baseline developed a cardiac event, while 45.5% of those with both a positive TnI and a history of CAD had an event. Fourteen deaths occurred over 2 years, 8 in TnI positive and 6 in the negative group. All-cause mortality was not associated with elevated TnI levels at baseline. We found a significant association between positive TnI and subsequent cardiac events in asymptomatic HD patients followed for 2 years. TnI levels, as measured with a sensitive assay, may be useful in assessing cardiac risk in asymptomatic HD patients. This needs further confirmation in a larger cohort.
- Published
- 2012
- Full Text
- View/download PDF
23. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
- Author
-
Vaghasiya RP, DeVita MV, and Michelis MF
- Subjects
- Aged, Aged, 80 and over, Arginine Vasopressin blood, Arginine Vasopressin drug effects, Benzazepines pharmacology, Blood Pressure drug effects, Diuretics pharmacology, Heart Failure blood, Heart Failure complications, Heart Failure urine, Humans, Hyponatremia blood, Hyponatremia urine, Inappropriate ADH Syndrome blood, Inappropriate ADH Syndrome complications, Inappropriate ADH Syndrome urine, Osmolar Concentration, Sodium blood, Tolvaptan, Antidiuretic Hormone Receptor Antagonists, Benzazepines therapeutic use, Diuretics therapeutic use, Hyponatremia drug therapy
- Abstract
Tolvaptan, an oral, selective arginine vasopressin (AVP) V2 receptor antagonist has been approved for the treatment of euvolemic and hypervolemic hyponatremia in the United States. This report summarizes our center's experience with thirteen patients treated for hyponatremia with one 15-mg dose of tolvaptan. The patients had euvolemic or hypervolemic hyponatremia with decreased serum osmolality and serum sodium (SNa) levels less than 129 mEq/L. Eight patients had a diagnosis of the syndrome of inappropriate antidiuretic hormone (SIADH), and five patients had a diagnosis of congestive heart failure (CHF). Results revealed an increase in SNa in all patients from 122.5 ± 4.2 to 128.9 ± 4.1 mEq/L (P < 0.05). The mean increase in SNa of 6.4 mEq/L (range 2-10 mEq/L) 24 h post-tolvaptan was not different in the two groups of patients, but SIADH patients had higher pre and post-tolvaptan SNa levels than CHF patients. Urine osmolalities (UOsm) decreased in all patients, and the patients with SIADH had significantly higher baseline UOsm and a larger decrease in UOsm 12 h post-tolvaptan administration when compared with the CHF patients. AVP levels did not change post-tolvaptan administration. However, the magnitude of increase in SNa levels was inversely related to pretolvaptan AVP levels in the SIADH subgroup (r = -0.7, P = 0.01). Three SIADH patients received small amounts of D5W to attenuate changes in SNa. No significant changes in mean arterial pressure, serum potassium, serum glucose, and blood urea nitrogen or serum creatinine were observed. The data show that tolvaptan is effective for the treatment of hyponatremia and may produce differing responses in disparate patient groups.
- Published
- 2012
- Full Text
- View/download PDF
24. Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R).
- Author
-
Paulson WD, Kipshidze N, Kipiani K, Beridze N, DeVita MV, Shenoy S, and Iyer SS
- Subjects
- Adolescent, Adult, Aged, Coated Materials, Biocompatible, Collagen metabolism, Female, Follow-Up Studies, Humans, Hypertension mortality, Male, Microscopy, Electron, Scanning, Middle Aged, Safety, Survival Rate, Thrombosis prevention & control, Young Adult, Blood Vessel Prosthesis Implantation, Drug Delivery Systems, Hypertension drug therapy, Polytetrafluoroethylene, Renal Dialysis, Sirolimus administration & dosage, Vascular Patency drug effects
- Abstract
Background: Neointimal hyperplasia causes a high rate of hemodialysis synthetic graft failure. Thus, therapies that inhibit neointimal hyperplasia are urgently needed. The Coll-R is a sirolimus-eluting collagen matrix designed for intra-operative perivascular implantation around the graft-venous anastomosis. Sirolimus is an anti-proliferative drug that has proven clinical utility in suppressing neointimal tissue growth in coronary artery disease when delivered locally to the vascular wall by an endovascular drug eluting stent., Methods: A cohort of 12 chronic hemodialysis patients underwent surgical placement of 13 polytetrafluoroethylene grafts + Coll-R and were followed for up to 24 months. The primary endpoint was safety (freedom from device related adverse events). Secondary endpoints were pharmacokinetics of sirolimus release, success of Coll-R implantation and primary unassisted graft patency., Results: There were no technical failures, infections, vascular anastomotic or wound-healing problems. Whole blood sirolimus levels rose to a mean peak of 4.8 ng/mL at 6 h and fell to <1 ng/mL at 1 week (n = 5). Twelve and 24-month primary unassisted patencies were 76 and 38%, respectively, and the thrombosis rate was 0.37/patient-year., Conclusions: Perivascular implantation of the Coll-R during graft surgery safely delivered sirolimus to the vascular wall. Systemic sirolimus levels were sub-therapeutic for immunosuppression. This small first-in-human study supports the concept that the Coll-R can safely deliver sirolimus to the graft-venous anastomosis. Safety and patency in this small study were sufficiently encouraging to justify randomized controlled trials to further test the efficacy of the Coll-R.
- Published
- 2012
- Full Text
- View/download PDF
25. Troponin I levels in asymptomatic patients on haemodialysis using a high-sensitivity assay.
- Author
-
Kumar N, Michelis MF, DeVita MV, Panagopoulos G, and Rosenstock JL
- Subjects
- Aged, Female, Humans, Kidney Failure, Chronic therapy, Male, Middle Aged, Prospective Studies, Time Factors, Kidney Failure, Chronic blood, Renal Dialysis methods, Troponin I blood
- Abstract
Background: Troponin I (TnI) is an effective marker for detecting myocardial injury, but the interpretation of levels in the setting of end-stage renal disease (ESRD) is still unclear. TnI levels have been noted to be increased in 5-18% of asymptomatic haemodialysis (HD) patients with standard assays, but newer-generation, high-sensitivity assays have not been examined. In addition, there is limited data on the variability of TnI levels in patients over time as well as the effect of HD on TnI levels. The aim of this study was to prospectively explore the incidence of TnI with a high-sensitivity assay, the variability of TnI levels over time and the effect of HD on levels., Methods: We enrolled 51 asymptomatic HD patients and checked TnI levels using a high-sensitivity assay. Levels were drawn pre-HD monthly for three consecutive months. As per manufacturer guidelines, levels were considered normal up to 0.034 ng/mL, indeterminate elevation (IE) if between 0.035 and 0.120 ng/mL and consistent with myocardial infarction (MI) if >0.120 ng/mL. In the third month, post-HD TnI was also drawn to determine change with dialysis., Results: At baseline, median TnI level was 0.025 ng/mL (range, 0-0.461 ng/mL). Baseline TnI levels were normal in 63% and elevated (≥0.035 ng/mL) in 37%. Of those with elevations, 79% were in the IE range and 21% in the acute myocardial infarction range. Higher TnI levels at baseline were associated with a history of coronary artery disease, left ventricular hypertrophy, lower cardiac ejection fraction and higher serum phosphate levels. Average incidence of elevated TnI was 41% over the 3 months. Thirty-six patients had stable levels without a change in classification over 3 months. Twelve varied over time. Forty-five (94%) had no change in classification pre- and post-HD., Conclusion: Using a new-generation, high-sensitivity assay, over a third of asymptomatic ESRD patients have an elevated TnI. The significance of these low-level elevations is unclear at this time. TnI levels remain stable over a 3-month period in most patients. HD treatment does not appear to affect the TnI level.
- Published
- 2011
- Full Text
- View/download PDF
26. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease.
- Author
-
Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Malieckal D, DeVita MV, and Michelis MF
- Subjects
- Aged, Chronic Disease, Double-Blind Method, Humans, Incidence, Retrospective Studies, Contrast Media adverse effects, Heart Failure complications, Kidney Diseases chemically induced, Sodium Bicarbonate
- Abstract
We randomized patients with chronic kidney disease (serum creatinine ≥ 1.5 mg/dl or glomerular filtration rate (GFR) <60 ml/min/1.73 m²) in a double-blind fashion to receive saline or sodium bicarbonate prior to and after cardiac or vascular angiography. The primary endpoint was contrast-induced nephropathy (CIN), defined as an increase in serum creatinine by 25% or by 0.5 mg/dl from baseline. Patients with congestive heart failure (CHF), cardiac ejection fraction (EF) <30%, or GFR < 20 ml/min/1.73 m² were excluded. The study was discontinued (after 142 patients were randomized) due to a low incidence of CIN (1.5%). We retrospectively identified all cases of CIN (n = 30) at our institution during the same time period to see if these patients differed from our trial sample. There was no difference in serum creatinine (1.7 ± 0.4 vs. 1.7 ± 0.6 mg/dL), GFR (42.7 ± 9.7 vs. 45.3 ± 3.2 ml/min), incidence of diabetes (51.8% vs. 63.3%), contrast volume (121.7 ± 63.8 vs. 122.7 ± 68.3 ml), ACE inhibitor or angiotensin receptor blocker use (54.0% vs 63.3%), and periprocedure diuretic use (33.1% vs 26.7%). On multivariate analysis, only a cardiac ejection fraction (EF) of less than 40% was significantly associated with CIN (odds ratio, 4.52; 95% confidence interval, 1.30-15.71; P = 0.02). In all, 22/30 patients (73.3%) who developed CIN had at least one or more characteristics that would have excluded their enrollment in our randomized trial including evidence of congestive heart failure (17/30 patients), EF less than 30% (9 patients), age greater than 85 years (2 patients), or advanced renal failure with a baseline GFR of less than 20 cc/min (1 patient). In summary, patients with CKD without evidence of CHF who receive adequate hydration appear to have a very low risk of CIN associated with angiography. A low EF (less than 40%) appeared to be the most significant risk factor for CIN in our population.
- Published
- 2010
- Full Text
- View/download PDF
27. A case of bovine ketoacidosis in a lactating woman.
- Author
-
Sandhu HS, Michelis MF, and DeVita MV
- Abstract
A 36 year-old 5 weeks postpartum lactating woman presented to the emergency room with severe nausea and vomiting for 48 hours. The patient was found to be in non-diabetic ketoacidosis with a serum pH 6.9 and a HCO3 of <5mEq/L. This condition rapidly improved with the administration of intravenous dextrose and bicarbonate and with the cessation of breast feeding. The course and pathophysiology of the rarely described phenomenon of bovine ketosis in a human is discussed here.
- Published
- 2009
- Full Text
- View/download PDF
28. Hyponatremia associated with large-bone fracture in elderly patients.
- Author
-
Sandhu HS, Gilles E, DeVita MV, Panagopoulos G, and Michelis MF
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Incidence, Male, Fractures, Bone etiology, Hyponatremia complications, Hyponatremia epidemiology
- Abstract
Hyponatremia has been shown to be associated with gait disturbances, decreased mentation, and falls. The study objective was to determine the incidence of hyponatremia in patients who experienced a substantial skeletal fracture (hip/pelvis/femur). During an 18-month period from March 2007 to August 2008 serum sodium levels were evaluated in 364 cases of bone fracture in patients aged 65 years or older and in 364 nonfracture patients aged 65 years and older seen in an urban emergency room setting. The incidence of hyponatremia in patients with fractures was more than double that of nonfracture patients (9.1% and 4.1%, respectively; P = 0.007). The degree of hyponatremia was noted to be mild to moderate. Mean serum sodium of the entire fracture group was 131 +/- 2 mEq/L. In the fracture group the patients were 75.3% female, while females comprised 66.2% of the nonfracture group (P = 0.02). Of fracture patients with hyponatremia, 24.2% were taking antidepressants [3/4 of which were selective serotonin receptor inhibitors (SSRIs)], while none were taking these medications in the nonfracture group. Attention regarding careful follow-up of serum sodium levels in elderly patients seems appropriate.
- Published
- 2009
- Full Text
- View/download PDF
29. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy.
- Author
-
Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, and Michelis MF
- Subjects
- Aged, Analysis of Variance, Creatinine blood, Female, Humans, Incidence, Male, Angiotensin II Type 1 Receptor Blockers administration & dosage, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Contrast Media adverse effects, Coronary Angiography, Kidney Diseases chemically induced, Kidney Failure, Chronic complications
- Abstract
Background: The effect of continuing or discontinuing chronic angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy prior to coronary angiography on the incidence of contrast-induced nephropathy (CIN) is not clear. We undertook a randomized trial to evaluate the effect of withdrawing ACEIs or ARBs 24 h prior to coronary angiography on the incidence of CIN associated with coronary angiography., Methods: A total of 220 patients with chronic kidney disease (CKD) stages 3-4 (glomerular filtration rate 15-60 ml/min/1.73 m2) on ACEI or ARB therapy were randomized before angiography to either ACEI/ARB continuation group or discontinuation group. A third group of patients with CKD stages 3-4 but not on angiotensin blockade therapy were also followed. The primary outcome measure was the incidence of CIN defined by a rise in serum creatinine by 25% or 0.5 mg/dl (44 micromol/l) from baseline., Results: There was no statistically significant difference in the incidence of CIN between the three groups (P=0.66). The incidences were 6.2%, 3.7%, and 6.3% for the continuation, discontinuation, and angiotensin blockade naïve group, respectively. There was also no significant difference found between the groups in mean serum creatinine and glomerular filtration rate values at baseline and post contrast administration., Conclusion: Withholding ACEIs and ARBs 24 h before coronary angiography does not appear to influence the incidence of CIN in stable patients with CKD stages 3-4.
- Published
- 2008
- Full Text
- View/download PDF
30. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.
- Author
-
Metzger BL, DeVita MV, and Michelis MF
- Subjects
- Aged, Aged, 80 and over, Benzazepines administration & dosage, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Treatment Outcome, Antidiuretic Hormone Receptor Antagonists, Benzazepines therapeutic use, Hyponatremia drug therapy
- Abstract
The treatment of hyponatremia, especially euvolemic and hypervolemic hyponatremia, has changed with the development of drugs which function as vasopressin receptor antagonists. These agents increase solute-free water excretion by the kidney resulting in an aquaresis. Conivaptan, a vasopressin receptor antagonist, has recently been approved by the FDA in the United States for use in the therapy of both euvolemic and hypervolemic hyponatremia. This report summarizes one center's experience with ten patients treated with this new drug. The patients had euvolemic hyponatremia with serum sodium levels less than 128 mEq/l. The same protocol was used in all patients with the conivaptan being given as a 20-mg intravenous loading dose followed by a 20-mg continuous 24-h infusion. Review of the data revealed that six of the ten patients had an excellent response to the therapy, with serum sodium increasing by a mean of 8.5+/-0.8 mEq/l (increases ranged from 7 to 12 mEq/l over 24 h). No significant changes in serum potassium levels or mean arterial pressures were noted. Two of the ten patients experienced a decrease in urine osmolality without a significant increase in serum sodium. Two other patients had only slight decreases in urine osmolality, and no significant increase in serum sodium levels. The data reveal that conivaptan is useful in the management of significant hyponatremia. There were no significant untoward effects, with the exception of one patient whose blood pressure decreased during the conivaptan infusion and who responded to cessation of the infusion and saline replacement therapy. This new class of drugs holds great promise for the treatment of dilutional hyponatremic disorders.
- Published
- 2008
- Full Text
- View/download PDF
31. Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease.
- Author
-
Dempster DW, Rosenstock JL, Schwimmer JA, Panagopoulos G, DeVita MV, and Michelis MF
- Subjects
- Cardiovascular Diseases etiology, Drug Utilization statistics & numerical data, Female, Humans, Male, Middle Aged, Aspirin administration & dosage, Cardiovascular Diseases prevention & control, Cyclooxygenase Inhibitors administration & dosage, Renal Dialysis adverse effects
- Abstract
Background: Patients on hemodialysis are at high risk for cardiovascular disease (CVD). Aspirin is an established therapy for primary and secondary prevention of CVD that may be underutilized in hemodialysis patients. To better understand the use of aspirin in hemodialysis patients, we examined the experience of an urban hemodialysis center. Guidelines for use as well as associated risks and benefits are reviewed., Methods: Medical records for patients receiving hemodialysis treatment at our center (New York City, USA) in May 2004 were reviewed for aspirin use, presence of CVD, and potential contraindications to aspirin therapy. CVD was defined as a history of coronary artery disease, ischemic stroke, transient ischemic attack, or peripheral vascular disease. Potential contraindications to aspirin therapy included history of clinically significant bleeding or increased risk of bleeding, aspirin allergy and routine treatment with other anticoagulants., Results: 176 patients were eligible for the study and 172 (98%) were included. Although 74 patients had a history of CVD, only 38 (51 %) of these were treated with aspirin. Among patients with a history of CVD who were not treated with aspirin, 19 (53%) had no identifiable contraindications to aspirin therapy for secondary prevention of CVD. Ninetyeight patients had no history of CVD, and 18 (18%) of these were treated with aspirin. Of patients without a history of CVD who were not treated with aspirin, 57 (71%) had no identifiable contraindications to aspirin therapy for primary prevention of CVD., Conclusions: Aspirin is underutilized in hemodialysis patients for the primary and secondary prevention of CVD. Given the high risk of CVD in hemodialysis patients, therapy with aspirin may be of significant benefit and prospective studies of aspirin therapy are needed.
- Published
- 2005
- Full Text
- View/download PDF
32. Pregnancy in peritoneal dialysis: a case report and review of adequacy and outcomes.
- Author
-
Smith WT, Darbari S, Kwan M, O Reilly-Green C, and Devita MV
- Subjects
- Adult, Female, Fetal Hypoxia diagnosis, Humans, Pregnancy, Ultrasonography, Prenatal, Kidney Failure, Chronic therapy, Peritoneal Dialysis, Pregnancy Complications therapy, Pregnancy Outcome, Pregnancy, High-Risk
- Abstract
A case of pregnancy in a 27-year-old woman on peritoneal dialysis is presented. The case report is a detailed description of her course including changes in her peritoneal dialysis regimen and the use of continuous cycling to maximize dialysis adequacy while addressing the patient's recurrent abdominal pain and fullness. Also described is the management of complications including hypertension, gestational diabetes, and premature rupture of membranes. The discussion reviews the diagnosis of pregnancy, factors that may relate to outcome, and a detailed comparison of pregnancy outcomes in patients on dialysis to the general population.
- Published
- 2005
- Full Text
- View/download PDF
33. Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns.
- Author
-
Dragovic D, Rosenstock JL, Wahl SJ, Panagopoulos G, DeVita MV, and Michelis MF
- Subjects
- Age Factors, Black People, Creatinine blood, Female, Glomerulonephritis, Membranoproliferative epidemiology, Glomerulonephritis, Membranous epidemiology, Hispanic or Latino, Humans, Japan epidemiology, Male, Nephrosis, Lipoid epidemiology, Proteinuria complications, Retrospective Studies, White People, Glomerulosclerosis, Focal Segmental epidemiology
- Abstract
Background: Idiopathic focal segmental glomerulosclerosis (FSGS) is one of the leading causes of the nephrotic syndrome in adults and an important cause of end-stage renal disease. Its incidence has dramatically increased in the last two decades and it is especially prevalent among black patients. The trend of FSGS incidence has not been reported beyond 1997., Methods: We retrospectively reviewed all renal biopsies performed at our institution between 1986 and 2002 and identified patients with diagnoses consistent with primary glomerulopathy (PG), which included: minimal-change disease (MCD), idiopathic focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MGN), IgA nephropathy (IgA), membrano-proliferative glomerulonephritis (MPGN) and mesangioproliferative glomerulonephritis. Patients with possible secondary causes for their renal disease were excluded. Clinical data at the time of biopsy and follow-up data were collected and analyzed., Results: During the period from January 1986-December 2002, 299 renal biopsies were performed and 132 patients were diagnosed with PG. FSGS was the most common form of PG representing 37.8% of all PG followed by IgA 27.3%, MGN 16.6% and MCD 9.1%. Among FSGS patients 59% were females, 64% had nephrotic range proteinuria and 54% had the nephrotic syndrome. Mean serum creatinine was 2.0 +/- 0.2 mg/dl and mean protein excretion was 6.1 +/- 1.0 g/day. The incidence of FSGS increased from 19.3% (1986-1991) and 16.6% (1992-1997) to 58.5% in the period from 2002. The increase occurred among black and Hispanic patients (33.3-79.2%) as well as white patients (12.5-51.5%). Black and Hispanic patients with PG presented for renal biopsy at a significantly younger age than white patients (p = 0.003), with mean age 37.5 +/- 2.0 years vs. 50.3 +/- 1.8 years. White FSGS patients were significantly older than white non-FSGS patients (mean age 56.4 +/- 3.2 years vs. 48.0 +/- 2.0 years, p = 0.03). Black and Hispanic FSGS patients were also older when compared to their non-FSGS counter-parts (mean age 40.6 +/- 2.8 years vs. 32.1 +/- 2.0 years, p = 0.04). When patients were stratified by age (< 45 years and > or = 45 years), FSGS was the most common diagnosis in both age groups among black and Hispanic patients (55.1% and 88.8%) but only among older white patients (36.2%)., Conclusions: The incidence of FSGS as a proportion of PG in our population has increased markedly in the most recent time period analyzed (1998-2002). The increase has occurred among both white and black and Hispanic patients. We also found that FSGS was most prevalent in patients > or = 45 years.
- Published
- 2005
- Full Text
- View/download PDF
34. Refractory hypotension and edema caused by right atrial compression in a woman with polycystic kidney disease.
- Author
-
Lasic LB, DeVita MV, Spiegel PJ, Marino ND, Mellow E, and Michelis MF
- Subjects
- Edema etiology, Female, Humans, Middle Aged, Nephrectomy, Polycystic Kidney Diseases surgery, Cysts complications, Heart Atria physiopathology, Hypotension etiology, Liver Diseases complications, Polycystic Kidney Diseases complications
- Abstract
We present the case of a 60-year-old woman with a history of autosomal dominant polycystic kidney disease and long-standing hypertension who developed persistent hypotension. While in the hospital for the treatment of bacteriemia, the patient had low systolic blood pressures (90 to 100 mm Hg), which was thought to be the consequence of infection. After the infection was adequately controlled and the blood pressure did not improve, an echocardiogram was done to further elucidate her hypotension. It was nondiagnostic and revealed an ejection fraction of 70% with left ventricular hypertrophy. Shortly after discharge, she developed significant lower extremity edema and her blood pressure remained low. Due to the low blood pressure it was not possible to mobilize the fluid with her dialysis treatments. A repeat transthoracic echocardiogram at that time revealed that the right atrium was partially compressed throughout the cardiac cycle by polycystic hepatic tissue. This tissue invaginated up through the right hemidiaphragm. A partial liver resection was considered for the patient. Instead, right nephrectomy was performed and the blood pressure improved.
- Published
- 2004
- Full Text
- View/download PDF
35. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
- Author
-
DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, and Michelis MF
- Subjects
- Adult, Aged, Aged, 80 and over, Anemia drug therapy, Anemia etiology, Female, Follow-Up Studies, Humans, Injections, Intravenous, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Male, Middle Aged, Prospective Studies, Erythropoietin administration & dosage, Ferritins blood, Iron-Dextran Complex administration & dosage, Renal Dialysis
- Abstract
Introduction: Although clinical use of recombinant human erythropoietin (rHuEPO) since 1989 has improved anemia in most end-stage renal disease patients, there are still many hemodialysis patients unable to maintain an adequate hematocrit (HCT) without large doses of rHuEPO. This suggests that anemia is not solely a consequence of rHuEPO deficiency, but may be due to other factors including functional iron deficiency. Since the optimal prescription for iron replacement is not yet known, we evaluated the effect of intravenous iron dextran (IVFe) infusion on serum ferritin (SFer) concentration and rHuEPO dose. Our objective was to raise and maintain serum ferritin concentrations to 2 different levels above the National Kidney Foundation Dialysis Outcome Quality Initiative standard of 100 ng/ml to determine whether, and by what degree rHuEPO dose could be lowered., Methods: HD patients on i.v. rHuEPO with a SFer concentration > or = 70 ng/ml and an HCT of < or = 33% were enrolled. Subjects were divided as follows: Group 1: target SFer of 200 ng/ml, Group 2: target SFer of 400 ng/ml. Each subject below the target level received IVFe in up to 10 divided doses during consecutive dialysis sessions as needed to reach the target. HCT was maintained between 32.5% and 36% by adjusting rHuEPO dosage., Results: Mean SFer concentration at the study conclusion in Group 1: 261 ng/ml; Group 2: 387 ng/ml. The mean decrease in rHuEPO dose for Group 1 was 31 U/kg body weight/week (250 - 219 U/kg bw/wk) while in Group 2 it was 154 U/kg body weight/week (312 - 158 U/kg bw/wk) (p < 0.001). There was no difference in HCT between groups. Our results suggest that higher target serum ferritin concentrations can be well tolerated and lower rHuEPO requirements.
- Published
- 2003
- Full Text
- View/download PDF
36. Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanism.
- Author
-
Panos J, Michelis MF, DeVita MV, Lavie RH, and Wilkes BM
- Subjects
- Adult, Aged, Aged, 80 and over, Aldosterone blood, Disease Progression, Drug Therapy, Combination, Female, Humans, Kidney Diseases blood, Kidney Diseases drug therapy, Losartan administration & dosage, Male, Middle Aged, Proteinuria etiology, Renin blood, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Kidney Diseases urine, Proteinuria prevention & control
- Abstract
Patients with various renal diseases receiving an angiotensin-converting enzyme inhibitor (CEI) were enrolled in a protocol to determine whether adding an angiotensin type 1 receptor blocker (ARB) reduces urinary protein excretion (UPE). All patients had significant proteinuria (range 517-8,562 mg/24 h) despite administration of CEI for at least 4 weeks. Following baseline measurements, losartan (50 mg/d) was started and testing was repeated at 1 month. Compared with CEI alone, combined CEI plus ARB reduced UPE by 45 +/- 8% (p < 0.005). Compared with CEI alone, CEI + ARB lowered UPE in each patient independent of baseline protein excretion or renal diagnosis. Reduction in proteinuria occurred independent of changes in mean arterial blood pressure (MAP), suggesting that the mechanism involved local changes in glomerular dynamics. If renal angiotensin II (ANG II) formation occurred despite CEI, the ANG II formed would suppress plasma renin activity (PRA), and adding an ARB would cause PRA to rise. In 7 of 10 subjects, addition of ARB to CEI increased PRA (p < 0.03) suggesting that intrarenal ANG II formation occurred in CEI-treated subjects. As a second marker of ANG II tissue activity, we measured the effects adding ARB on plasma aldosterone (ALDO). In 9 of 10 subjects, ALDO was acutely lowered (p < 0.009) suggesting that ANG II levels were incompletely blocked by CEI. We conclude that: combined CEI and ARB reduces UPE greater than CEI alone; reduction in proteinuria is independent of changes in MAP or renal diagnosis; and the additive effects of CEI and ARB are due at least in part to greater inhibition ofANG II action at the tissue level in the kidneys and adrenal glomerulosa.
- Published
- 2003
- Full Text
- View/download PDF
37. Failure of intravenous fluid therapies to decrease serum sodium levels in elderly hospitalized patients.
- Author
-
Krishnan S, DeVita MV, Panagopoulos G, and Michelis MF
- Subjects
- Aged, Aged, 80 and over, Creatinine blood, Female, Humans, Male, Osmolar Concentration, Sodium blood, Treatment Failure, Fluid Therapy, Hyponatremia therapy
- Abstract
Elderly patients may have a tendency to develop hyponatremia due to sensitivity to stimuli that release ADH as well as an impaired ability to excrete a water load. We evaluated changes in serum sodium in elderly hospitalized patients who received various forms of intravenous fluid therapies. All patients were required to have a baseline serum sodium of 136-145 meq/L. Fourteen patients were enrolled in the study. The mean age was 82.9 +/- 6.8 years (mean +/- SEM). Thirty-six % were nursing home residents. Seventy-nine % were females. Seventy-two % received half normal saline and the remainder received normal saline as intravenous fluid therapy. The patients received a mean of 1098 +/- 145 mL of intravenous fluid per day, in addition to oral fluids. Mean follow up period was 5.9 days (3-10 days). Mean baseline serum sodium was 140.2 +/- 0.7 meq/L andmean follow up serum sodium was 141.4 +/- 0.9 meq/L. The m ean baseline BUN was 25 +/- 3.6 mg/dL and mean follow u BUN was 19.6 +/- 3.4 mg/dL. The mean baseline serum creatinine was 0.9 +/- 0.1 mg/dL and mean follow up creatinine was 0.9 +/- 0.1 mg/dL. The postintravenous fluid therapy serum sodium in the group receiving half normal saline was 141.7 +/- 0.7 meq/L and 140.8 +/- 3 meq/L in the normal saline group. No significant difference was observed between the pre and post fluid therapy for any of these paramenters (p > 0.05). Mean baseline plasma renin activity was 1.6 +/- 0.7 ng/ml/hour and fifty-seven % had PRA of less than 1 ng/ml/hour. Mean plasma aldosterone was 8.5 +/- 1.8 ng/mL and forty-two % were less than 5.5 ng/mL. Plasma ADH and ANP was 5.7 +/- 3.4 pg/mL and 83.6 +/- 26.9 pg/mL, respectively. Mean serum and urine osmolalities were 290 +/- 3.1 mOsm/kg and 471 +/- 57.7 mOsm/kg, respectively. No patient developed hyponatremia and 7 of the 14 patients experienced an increase in serum sodium during the follow up period. We conclude that many elderly patients hospitalized for acute medical illnesses either maintain a stable serum sodium or experience an increase in serum sodium. This occurs because total fluids administered to these patients are generally insufficient.
- Published
- 2002
- Full Text
- View/download PDF
38. Assessment of sonographic venous peak systolic velocity in detecting hemodialysis arteriovenous graft stenosis.
- Author
-
DeVita MV, Ky AJ, Fried KO, Vogel FE, and Michelis MF
- Subjects
- Angiography, Digital Subtraction, Female, Fluoroscopy, Humans, Male, Middle Aged, Prospective Studies, Systole, Vascular Patency, Arteriovenous Shunt, Surgical, Blood Flow Velocity, Graft Occlusion, Vascular etiology, Renal Dialysis methods, Ultrasonography, Doppler, Color
- Abstract
There is no single effective means of assessing arteriovenous access function, although monitoring hemodialysis venous pressure (VP) or measuring access recirculation may be of some benefit. The present study assesses prospectively the efficacy of following the peak systolic velocity (PSV) as a single measure to detect arteriovenous graft (AVG) stenosis. PSV was measured in 12 patients after new AVG placement and at approximately 2-month intervals. Angiography was also performed after new graft placement and when PSV was elevated to greater than 200 cm/sec, hemodialysis access VP increased to greater than 150 mm Hg on three consecutive readings, or access recirculation increased to greater than 11%. PSV was then compared with results from angiography, VP monitoring, and access recirculation. The 12 patients underwent 34 PSV studies, followed by angiography on 25 occasions. Each patient underwent at least one angiogram. Each abnormal PSV value was confirmed with the finding of stenosis on angiogram, except for two patients with PSVs greater than 400 cm/sec and normal angiography results. VP and recirculation were not elevated. During this period, two patients developed thrombosis of the AVG, and two patients underwent angioplasty with improvement in PSV. We conclude that elevations in PSV measured at the venous anastomosis are an effective means of screening for AVG stenosis, AVG stenosis can occur early after AVG placement, and elevated VP and recirculation are late findings in AVG dysfunction.
- Published
- 2000
- Full Text
- View/download PDF
39. Body composition assessed by neutron activation analysis in dialysis patients.
- Author
-
Stall S, DeVita MV, Ginsberg NS, Frumkin D, Lynn RI, and Michelis MF
- Subjects
- Adult, Body Fluid Compartments physiology, Female, Humans, Kidney Failure, Chronic complications, Male, Middle Aged, Morbidity, Neutron Activation Analysis methods, Nitrogen analysis, Proteins analysis, Body Composition, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic therapy, Peritoneal Dialysis, Renal Dialysis
- Abstract
Malnutrition is prevalent in end-stage renal disease (ESRD) patients treated with hemodialysis (HD) and peritoneal dialysis (PD). In addition, there is increased incidence of morbidity in this group. Evaluation of nutritional status is important. Application of body composition in the ESRD population to evaluate body compartments and to assess nutritional health has become more common in clinical practice. Neutron activation analysis (NAA) may provide data on metabolically active tissue by quantification of total body potassium (TBK) for body cell mass and assessment of protein by total body nitrogen (TBN). This method may be able to detect changes in body composition before clinical signs of malnutrition are apparent. Ten HD (5 male and 5 female) and 10 PD patients (7 male and 3 female) were evaluated by NAA, TBK, and isotope dilution. Female PD patients had an increased total body water (TBW) and increased intracellular water compared to HD females. Albumin was lower in PD women. There was no significant difference between PD men and laboratory controls in TBW, extracellular water, and TBN. The clinical application of body composition methods for evaluation of dialysis patients by serial assessment and for development of a bedside tool needs further study.
- Published
- 2000
- Full Text
- View/download PDF
40. Dual-energy X-ray absorptiometry: a review.
- Author
-
DeVita MV and Stall SH
- Subjects
- Body Water, Bone Density, Humans, Kidney Failure, Chronic therapy, Nutritional Status, Absorptiometry, Photon trends, Body Composition, Renal Dialysis
- Abstract
Dual-energy X-ray absorptiometry (DXA) has been recently used for body composition analysis in dialysis patients. It is based on the principle that X-rays passed through various body tissues have different attenuation and, therefore, can be differentiated. By using X-rays at two different energy levels, better tissue differentiation is possible compared with single energy systems. This article will review the evolution of DXA scanners and the role DXA has in assessing body composition in dialysis patients. Overall, this technique has excellent precision and holds promise for use in the serial evaluation of body composition and nutritional evaluation of dialysis patients.
- Published
- 1999
- Full Text
- View/download PDF
41. Renin-aldosterone system can respond to furosemide in patients with hyperkalemic hyporeninism.
- Author
-
Chan R, Sealey JE, Michelis MF, Swan A, Pfaffle AE, Devita MV, and Zabetakis PM
- Subjects
- Adult, Aged, Aged, 80 and over, Antihypertensive Agents therapeutic use, Atrial Natriuretic Factor blood, Captopril therapeutic use, Enzyme Precursors blood, Female, Humans, Hyperkalemia blood, Male, Middle Aged, Treatment Outcome, Aldosterone blood, Diuretics therapeutic use, Furosemide therapeutic use, Hyperkalemia drug therapy, Renin blood
- Abstract
Thirty-four patients (65.3+/-3.3 years of age, mean+/-SEM) with hyperkalemia (serum potassium >5.0 mEq/L) had measurement of their renin-aldosterone system. Nineteen patients (56%) had plasma renin activity (PRA) >1.5 ng/mL/h, which was not low, while 15 (44%) had PRA <1.5. Twelve of the 15 hyporeninemic hyperkalemic patients were studied to determine whether their renin-aldosterone system responded to 2 weeks of furosemide, 20 mg daily. Four were nonresponders: PRA averaged 0.3+/-0.1 ng/mL/h, and it did not increase with furosemide or respond to captopril before or after furosemide. Eight patients were responders: PRA averaged 0.6+/-0.2 ng/mL/h and increased with furosemide to 5.5+/-3.4 ng/mL/h. Captopril failed to increase PRA before furosemide, but PRA increased to 15.3+/-8.4 ng/mL/h after furosemide. Plasma aldosterone was low in both nonresponders and responders (3.5+/-1.2 ng/dL vs 5.8+/-2.5 ng/dL) and did not increase significantly with furosemide (4.3+/-1.7 ng/dL vs 8.7+/-2.5 ng/dL). Serum potassium did not fall and therefore did not limit the rise in aldosterone. Renin responders had greater body weight, were predominantly female (6/8 vs 2/4) and were more likely to have diabetes mellitus (7/8 vs 0/4). Plasma atrial natriuretic peptide (ANP) fell with furosemide in 8 of 8 responders and in 1 of the 2 nonresponders in whom it was measured. Neither group had suppressed plasma prorenin levels, indicating no suppression of renin gene expression. These results indicate that many hyperkalemic patients do not have suppressed PRA. Further, a majority of patients with suppressed PRA have high levels of ANP and can respond to diuretic therapy with a rise in PRA and a fall in ANP, suggesting physiologic suppression of the renin system by volume expansion. A minority of hyperkalemic patients with suppressed PRA had PRA that did not increase under these study conditions.
- Published
- 1998
- Full Text
- View/download PDF
42. Percentage body fat determination in hemodialysis and peritoneal dialysis patients: a comparison.
- Author
-
Stall S, Ginsberg NS, DeVita MV, Zabetakis PM, Lynn RI, Gleim GW, Wang J, Pierson RN, and Michelis MF
- Subjects
- Absorptiometry, Photon, Adult, Body Mass Index, Electric Impedance, Female, Humans, Male, Middle Aged, Potassium analysis, Prospective Studies, Adipose Tissue, Body Composition, Peritoneal Dialysis, Renal Dialysis
- Abstract
Objective: To evaluate percentage body fat in hemodialysis (HD) and peritoneal dialysis (PD) patients., Design: A prospective study of 20 HD patients and 20 PD patients., Setting: Sol Goldman Renal Therapy Center, Lenox Hill Hospital, New York, NY; Baumritter Kidney Center Albert Einstein College of Medicine, Bronx, NY; Body Composition Unit, St Luke's Roosevelt Hospital, Columbia University, New York, NY., Patients: Twenty HD (10 men, 10 women) patients, mean age 41.8 +/- 2.4 years and 20 PD (12 men, 8 women) patients, mean age 48.6 years +/- 3.0 years., Intervention: This is a noninterventional study. PATIENTS signed consent to undergo dual-energy x-ray absorptiometry, total body potassium counting bioelectrical impedance analysis, total body water determination, and anthropmetric evaluation., Main Outcome Measures: Present and compare percentage body fat between HD and PD patients as determined by the methods used., Results: Percentage fat is not different between HD and PD patients. Differences in absolute values of percent fat between techniques exist., Conclusion: HD patients and PD patients may be evaluated by the methods of body composition used. Percentage body fat will vary among techniques; therefore the same method should be used to follow a patient over time.
- Published
- 1998
- Full Text
- View/download PDF
43. Simplified measurement of intra-access pressure.
- Author
-
Besarab A, Frinak S, Sherman RA, Goldman J, Dumler F, Devita MV, Kapoian T, Al-Saghir F, and Lubkowski T
- Subjects
- Arteriovenous Shunt, Surgical, Blood Pressure, Blood Vessel Prosthesis, Calibration, Cohort Studies, Constriction, Pathologic diagnosis, Equipment Design, Equipment Failure, Humans, Monitoring, Physiologic instrumentation, Renal Dialysis adverse effects, Reproducibility of Results, Transducers, Catheters, Indwelling adverse effects, Pressure, Renal Dialysis instrumentation
- Abstract
The measurement of intra-access pressure (P[IA]) normalized by mean arterial BP (MAP) helps detect venous outlet stenosis and correlates with access blood flow. However, general use of P(IA)/MAP is limited by time and special equipment costs. Bernoulli's equation relates differences between P(IA) (recorded by an external transducer as PT) and the venous drip chamber pressure, PDC; at zero flow, the difference in height (deltaH) between the measuring sites and fluid density determines the pressure deltaPH = P(IA) - P(DC) Therefore, P(DC) and PT measurements were correlated at six different dialysis units, each using one of three different dialysis delivery systems machines. Both dynamic (i.e., with blood flow) and static pressures were measured. Changes in mean BP, zero calibration errors, and hydrostatic height between the transducer and drip chamber accounted for 90% of the variance in P(DC), with deltaPH = -1.6 + 0.74 deltaH (r = 0.88, P < 0.001). The major determinants of static P(IA)/MAP were access type and venous outflow abnormalities. In grafts, flow averaged 555 +/- 45 ml/min for P(IA)/MAP > 0.5 and 1229 +/- 112 ml/min for P(IA)/MAP < 0.5. DeltaPH varied from 9.4 to 17.4 mmHg among the six centers and was related to deltaH between the drip chamber and the armrest of the dialysis chair. Concordance between values of P(IA)/MAP calculated from PT and from P(DC) + deltaPH was excellent. It is concluded that static P(DC) measurements corrected by an appropriate deltaPH can be used to prospectively monitor hemodialysis access grafts for stenosis.
- Published
- 1998
- Full Text
- View/download PDF
44. Acute decrease in plasma potassium concentration following intravenous mannitol as a result of hemodilution in stable chronic hemodialysis patients.
- Author
-
Swan AM, DeVita MV, and Michelis MF
- Subjects
- Albumins pharmacology, Blood Volume drug effects, Humans, Osmolar Concentration, Renal Dialysis, Sodium Chloride pharmacology, Time Factors, Hemodilution methods, Kidney Failure, Chronic blood, Mannitol administration & dosage, Potassium blood
- Published
- 1997
45. Perturbations in sodium balance. Hyponatremia and hypernatremia.
- Author
-
DeVita MV and Michelis MF
- Subjects
- Diagnosis, Differential, Humans, Hypernatremia diagnosis, Hypernatremia physiopathology, Hypernatremia therapy, Hyponatremia diagnosis, Hyponatremia physiopathology, Hyponatremia therapy
- Abstract
Perturbations of serum sodium concentration are the most common electrolyte abnormalities seen in clinical medicine. Patients may exhibit profound alterations in mental status or be asymptomatic. Appropriate diagnosis and treatment is essential to reducing morbidity from serum sodium abnormalities. This article reviews the etiology, symptoms, and treatment of hyponatremic and hypernatremic syndromes.
- Published
- 1993
46. Laboratory investigation of renal stone disease.
- Author
-
DeVita MV and Zabetakis PM
- Subjects
- Female, Humans, Male, Recurrence, Kidney Calculi chemistry, Kidney Calculi epidemiology, Kidney Calculi etiology, Kidney Calculi physiopathology, Kidney Calculi urine
- Abstract
Renal stone disease is a chronic disease associated with a high rate of recurrences and hospitalizations. Over the past three decades, the incidence of nephrolithiasis has increased by 60% to 75%. Because there is a significant amount of morbidity associated with development of stone disease, a comprehensive yet simple evaluation to determine the cause of the problem is warranted.
- Published
- 1993
47. Determining peritoneal dialysis prescriptions by employing a patient-specific protocol.
- Author
-
Zabetakis PM, Krapf R, DeVita MV, Gleim GW, and Michelis MF
- Subjects
- Adult, Aged, Blood Urea Nitrogen, Creatinine metabolism, Dialysis Solutions administration & dosage, Humans, Middle Aged, Prospective Studies, Serum Albumin analysis, Peritoneal Dialysis, Continuous Ambulatory methods
- Abstract
Objective: To develop a formula that would permit a rapid and simple calculation of required dialysate volume needed to provide a predetermined daily creatinine clearance., Design: Prospective study of peritoneal dialysis patients followed for 6 months., Setting: A primary care teaching hospital in New York., Patients: Twenty-six patients beginning peritoneal dialysis entered and completed the study., Intervention: By employing each patient's measured peritoneal equilibration test (PET) and a standard clearance formula, a patient-specific treatment protocol (PSP) was calculated. The PET 2-hour D/Pcreat was used for continuous cycling peritoneal dialysis (CCPD) and the 4-hour D/Pcreat was used for patients on continuous ambulatory peritoneal dialysis (CAPD) to determine a PSP that would provide a minimum of 6 L of creatinine clearance daily., Main Outcome Measures: Patients were followed for 6 months to assess the ability of this approach of maintaining acceptable levels of blood urea nitrogen, creatinine, albumin, and hematocrit over the 6-month period of observation., Results: Our study of 26 patients revealed that only 6 patients (23%) could be treated with the standard prescription of 8 L/day on CAPD. The remaining 77% of our patients required 9-13 L/day for CAPD and 12-21 L/day for CCPD. All patients were free of uremic symptoms and demonstrated acceptable biochemical parameters over a 3-6 month period of observation., Conclusions: A patient-specific protocol utilizing individually derived PET data provides an acceptable and easy to calculate initial treatment prescription for each patient that avoids the necessity for trial and error that has heretofore been employed.
- Published
- 1993
48. Assessment of renal osteodystrophy in hemodialysis patients.
- Author
-
DeVita MV, Rasenas LL, Bansal M, Gleim GW, Zabetakis PM, Gardenswartz MH, and Michelis MF
- Subjects
- Absorptiometry, Photon standards, Alkaline Phosphatase blood, Aluminum blood, Biopsy, Calcium blood, Chronic Kidney Disease-Mineral and Bone Disorder epidemiology, Chronic Kidney Disease-Mineral and Bone Disorder etiology, Clavicle diagnostic imaging, Deferoxamine, Female, Hand diagnostic imaging, Hemodialysis Units, Hospital, Humans, Kidney Failure, Chronic therapy, Male, New York City epidemiology, Phosphorus blood, Prospective Studies, Sensitivity and Specificity, Chronic Kidney Disease-Mineral and Bone Disorder diagnosis, Kidney Failure, Chronic complications, Renal Dialysis
- Abstract
We performed a prospective study of 30 patients undergoing chronic hemodialysis to determine which of 6 generally available diagnostic procedures provided the most useful information for the assessment of bone disease in hemodialysis patients. The 6 procedures were: routine biochemical measurements, N-terminal parathyroid hormone (N-PTH), radiographic analysis of hands and clavicles, bone density determination by dual photon absorptiometry (DPA), deferoxamine stimulation test, and iliac crest bone biopsy. Serum N-PTH was elevated in 83% of patients but was not significantly associated with abnormalities of other biochemical parameters. No significant relationship was demonstrated between biochemical data and radiographic findings or between biochemical data and bone density by DPA. All patients with abnormal DPA had an elevation of N-PTH; therefore, DPA did not reveal any unsuspected disease. Bone biopsies were done in 20 patients and findings in each were consistent with uremic osteodystrophy, including osteitis fibrosa cystica in 11 patients and aluminum-associated bone disease in 2 patients. Six patients had mixed disease, and 1 patient had osteoporosis. Despite 11 positive deferoxamine tests, bone biopsy revealed aluminum deposition in only 7 of these patients, suggesting extraosseous aluminum accumulation in the remaining 4. Evaluation of the positive and negative predictive accuracies of DPA, x-ray analysis, N-PTH levels, and aluminum bone deposition revealed that normal DPA or x-ray findings do not exclude bone disease, that N-PTH level is a good marker for secondary hyperparathyroidism, and that a negative deferoxamine test excludes aluminum-associated bone disease. Discriminant analysis also reinforced these conclusions.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
49. Incidence and etiology of hyponatremia in an intensive care unit.
- Author
-
DeVita MV, Gardenswartz MH, Konecky A, and Zabetakis PM
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Hyponatremia etiology, Hyponatremia metabolism, Incidence, Male, Middle Aged, New York City epidemiology, Prospective Studies, Retrospective Studies, Hyponatremia epidemiology, Intensive Care Units
- Abstract
To evaluate the incidence and causes of hyponatremia in intensive care unit (ICU) patients, retrospective and prospective studies were done. Hyponatremia was defined as a serum sodium concentration equal to or less than 134 mmol/l (134 mEq/l). Prospectively, 29.6% of patients displayed hyponatremia. Relevant data were obtained in twelve patients. Two patients did not have serum hypoosmolality. In the ten patients with serum hypoosmolality, urine osmolality was not maximally dilute and urine sodium concentration was greater than 30 mmol/l (30 mEq/l) suggesting inappropriate antidiuretic hormone secretion (SIADH). However, three patients exhibited suppressed ADH levels despite absence of maximal urinary dilution. The data suggest that hyponatremia is common in ICU patients and that renal diluting defects are frequent. Therefore, hypotonic fluid should be administered cautiously.
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.